Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Inga Hund, Maria Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, Tobias Ma, David Uhl, Felicitas R. Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Lutz Peter Mueller, Andreas Neubauer, Justus Duyster, Hartmut Dohner, Melanie Boerries, Heiko Becker, Michael Luebbert

Blood (2022) 140 (Supplement 1): 3383–3384.

https://doi.org/10.1182/blood-2022-163220

Published: 2022

Journal Articles

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Julia Stomper, Annette M. May, Tina E. Joeckel, Peter Bronsert, Martin Werner, Michael Lübbert

Blood (2019) 134 (Supplement_1): 4265.

https://doi.org/10.1182/blood-2019-128141

Published: 2019

Journal Articles

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Julia Stomper, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Annette Schmitt-Graeff, Michael Lübbert

Blood (2019) 134 (Supplement_1): 1422.

https://doi.org/10.1182/blood-2019-128231

Published: 2019

Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Blood (2017) 130 (Supplement 1): 4261.

https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Email alerts

ASH Publications

American Society of Hematology

Update search

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only